US EditionThe Opioid Crisis: when Will the First Non-Addictive Pain Medication Hit the Market?
Summary by Israel Hayom
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Journavx acts on pain nerves instead of the brain • Development took 27 years and cost billions of dollars • So far, it has been tested mainly on women and has not yet been approved for the prevention of chronic pain • Experts: "Not a full replacement for opioids, but an intermediate step"
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
